Holen Sie sich die Stockscreener-App
15.43
2.08%
-0.475
Climb Bio Inc Aktie (CLYM) Neueste Nachrichten
Oppenheimer Adjusts Price Target on Climb Bio to $25 From $18, Maintains Outperform Rating - Moomoo
H.C. Wainwright raises Climb Bio stock price target on drug data - Investing.com
Oppenheimer raises Climb Bio stock price target on IgAN data By Investing.com - Investing.com India
Oppenheimer raises Climb Bio stock price target on IgAN data - Investing.com
H.C. Wainwright Maintains Climb Bio(CLYM.US) With Buy Rating, Raises Target Price to $30 - Moomoo
Truist Financial Maintains Climb Bio(CLYM.US) With Buy Rating - Moomoo
A Quick Look at Today's Ratings for Climb Bio(CLYM.US), With a Forecast Between $25 to $40 - Moomoo
symbol__ Stock Quote Price and Forecast - cnn.com
CLYM Stock Price, Quote & Chart - ChartMill
Baird raises Climb Bio stock price target to $25 on trial data - Investing.com Canada
BTIG raises Climb Bio stock price target to $32 on phase 1 data - Investing.com Australia
Baird raises Climb Bio stock price target to $25 on trial data By Investing.com - Investing.com South Africa
BTIG raises Climb Bio stock price target to $32 on phase 1 data By Investing.com - Investing.com South Africa
Climb Bio Phase I Data Backs 12-Week Dosing Plan for IgA Nephropathy Drug - Yahoo Finance
Climb Bio Announces Positive Phase 1 Trial Outcomes for CLYM116 Targeting IgA Nephropathy - Kalkine Media
Baird Initiates Climb Bio(CLYM.US) With Buy Rating, Announces Target Price $25 - Moomoo
Climb Bio’s Kidney Disease Therapy Gets Support for Extended Dosing Schedule - Benzinga
Climb Bio rises on trial data for kidney drug (CLYM:NASDAQ) - Seeking Alpha
CLYM: CLYM116 shows robust, durable APRIL and IgA suppression with a favorable safety profile in phase I - TradingView
Climb Bio Shares Rise 17% After Phase 1 CLYM116 Trial Data - Yahoo Finance
Why is Climb Bio stock sliding today? By Investing.com - Investing.com Canada
Climb Bio Reports Encouraging Initial Phase 1 CLYM116 Data - TipRanks
Climb Bio stock surges 17% on positive drug trial results - Investing.com
Climb Bio stock surges 17% on positive drug trial results By Investing.com - Investing.com India
Climb Bio reports phase 1 data for IgA nephropathy drug By Investing.com - Investing.com Nigeria
Climb Bio reports phase 1 data for IgA nephropathy drug - Investing.com
Climb Bio Announces CLYM116 Phase 1 Data Demonstrating - GlobeNewswire
Climb Bio to Present at Upcoming Investor Conferences - markets.businessinsider.com
Climb Bio Stock Up In Pre-Market Ahead Of CLYM116 Data Tomorrow - RTTNews
Should Climb Bio’s IgA Nephropathy Phase 2 Partnership Shift How CLYM Investors View Its Pipeline Strategy? - simplywall.st
Climb Bio (CLYM) Advances Phase 2 Trial In China, Is The Valuation Already Priced In? - Yahoo Finance
Climb (CLYM) Move: Closes 5.09% Lower at $16.40 in the Latest Session; Market Levels: the Near-Term Reference Band Stretches From $15.58 to $17.22 at the CloseCall Resistance - vinanet.vn
Climb Bio stock price target raised to $24 by H.C. Wainwright - Investing.com Canada
Climb (CLYM) Session: Ends Higher by 1.53% at $17.28; Current Setup: the Current Price Sits Inside the Supplied Technical Range in the Latest ReadingDouble Bottom - vinanet.vn
Climb Bio's (CLYM) Outperform Rating Reiterated at Wedbush - MarketBeat
Climb Bio (NASDAQ:CLYM) Hits New 52-Week HighShould You Buy? - MarketBeat
Is Climb Bio’s (CLYM) Mixed Loss Trends Revealing a Shift in Its Investment Story? - simplywall.st
Do Climb Bio’s (CLYM) Mixed Loss Trends Reveal a Shifting Path to Sustainable Scale? - Yahoo Finance
Dimensional Fund Advisors LP Buys Shares of 104,437 Climb Bio, Inc. $CLYM - MarketBeat
Climb Bio, Inc. (CLYM): MPM BioImpact LLC reports 0% ownership in amendment - Stock Titan
Climb Bio Collaborator Beijing Mabworks Begins Phase 2 Trial Dosing for IgA Nephropathy in China - Kalkine Media
Climb Bio (NASDAQ:CLYM) Shares Up 8.2%Still a Buy? - MarketBeat
Climb Bio Advances Phase 2 Renal Disease Trial - TipRanks
Form 8K Climb Bio Inc For: 14 August By Investing.com - Investing.com Australia
Climb Bio and Mabworks begin dosing in Phase 2 trial for kidney disease in China - Investing.com
CLYM Q2 2026 Earnings: Narrower Loss Beats Estimates, Shares Rise 2.36%Management Tone Analysis - vinanet.vn
0.63%
3.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):